Compare ArcelorMittal SA (MT) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs Smith & Nephew plc — how do they compare? ArcelorMittal SA trades at $77.08 (market cap $58.51B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: ArcelorMittal SA is far larger — about 5× Smith & Nephew plc's market cap, and Smith & Nephew plc pays the higher dividend (2.85%). Which is the better fit depends on your goals.
| MT | SNN | |
|---|---|---|
Market Cap | $58.51B | $11.63B |
Sector | Basic Materials | Health |
52-Week High | $78.74 | $38.53 |
52-Week Low | $34.39 | $27.80 |
Enterprise Value | $68.08B | $14.66B |
Dividend Yield | 0.78% | 2.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $77.15, down 2.02% on the day, with a bullish technical signal from moving averages and a neutral RSI. The company reported mixed Q2 2026 earnings, missing EPS estimates but showing year-over-year sales growth. Recent news highlights expansion in steel capacity and strategic partnerships, while facing headwinds from weak Chinese demand and geopolitical risks in Ukraine. Cash flow trends show a narrowing net outflow, improving from 2023 levels.
The outlook is cautiously optimistic, supported by analyst consensus and European demand improvements, but risks from industry cyclicality and input cost pressures remain. Investment appeal hinges on execution of growth initiatives and macroeconomic stability in key markets.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
